Prevalence of COPD by Disease Severity in Men and Women in Northern Vietnam

Lâm, Hoàng Th Formula See Text; Ekerljung, Linda; Rönmark, Eva; Lundbäck, Bo

doi:10.3109/15412555.2014.898039

Cited by 20 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This trend has been observed in many studies [ 15 – 17 ] and can be explained by greater exposure to risk factors and physiological decrease in lung function with age. In epidemiological studies, high prevalence of COPD in the elderly has been reported widely, in age groups > 50 years [ 18 ], 55–70 years [ 19 ], ≥ 60 years [ 20 ], 75–84 years [ 21 ], ≥ 70 years [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…The COPD prevalence estimates based on spirometry reported in this study were similar to the data published in previous studies (45 in Spain [ 16 ], 42 in USA [ 19 ] and 37 in United Arab Emirates [ 22 ] per 1000). Some other studies reported higher estimates (240 (The Netherlands) [ 23 ], 218 (Russia) [ 26 ], 197 (Uruguay) [ 20 ], 184 (Greece) [ 15 ], 162 (Uganda) [ 27 ], 162 (Sweden) [ 21 ], 142 (Portugal) [ 28 ], 134 (Korea) [ 17 ], 78 (Mexico) [ 20 ] and 71 (Vietnam) [ 18 ] per 1000). The variability in prevalence estimates could reflect true differences or be due to the different methodologies used in different studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The prevalence, burden and risk factors associated with chronic obstructive pulmonary disease in Commonwealth of Independent States (Ukraine, Kazakhstan and Azerbaijan): results of the CORE study

Nugmanova

Feshchenko²,

Iashyna³

et al. 2018

BMC Pulm Med

View full text Add to dashboard Cite

BackgroundIn the Commonwealth of Independent States (CIS) countries the epidemiology of chronic obstructive pulmonary disease (COPD) is poorly characterized. The objective of this analysis is to present the prevalence, burden and risk factors associated with COPD in three CIS countries as part of the CORE study (Chronic Obstructive Respiratory Diseases), the rationale and design of which have been described elsewhere.MethodsA total of 2842 adults (≥18 years) were recruited (964 in Ukraine, Kiev, 945 in Kazakhstan, Almaty and 933 in Azerbaijan, Baku) between 2013 and 2015 during household visits. Two-step cluster randomization was used for the sampling strategy. All respondents were interviewed about respiratory symptoms, smoking status and medical history, and underwent spirometry with bronchodilator. COPD was defined as (i) “previously diagnosed” when the respondent reported that he/she had previously been diagnosed with COPD by a doctor, (ii) “diagnosed by spirometry” using the GOLD criteria (2011) based on spirometry conducted during the study (FEV1/FVC < 0.70), and (iii) “firstly diagnosed by spirometry”, when the patient had received the COPD diagnosis for the first time based on the spirometry results obtained in this study.ResultsThe prevalence of “previously diagnosed” COPD was 10.4, 13.8 and 4.3 per 1000, and the prevalence of COPD “diagnosed by spirometry” was 31.9, 66.7 and 37.5 per 1000 in Ukraine, Kazakhstan, and Azerbaijan, respectively. Almost all respondents with COPD were diagnosed for the first time during this study. A statistically significant relationship was shown between smoking and COPD in Kazakhstan (odds ratio, OR: 3.75) and Azerbaijan (OR: 2.80); BMI in Ukraine (OR: 2.10); tuberculosis in Ukraine (OR: 32.3); and dusty work in Kazakhstan (OR: 2.30). Co-morbidities like cardiovascular diseases and a history of pneumonia occurred significantly (p < 0.05) more frequently in the COPD population compared to the non-COPD population across all participating countries. For hypertension, this was the case in Ukraine and Azerbaijan.ConclusionIn CIS countries (Ukraine, Kazakhstan and Azerbaijan), the prevalence of COPD “diagnosed by spirometry” was significantly higher than the prevalence of previously diagnosed COPD. Compared to many other countries, the prevalence of COPD seems to be relatively low in CIS countries. Factors such as limited funding from the government; lack of COPD knowledge and the attitude within the population, and of primary care physicians; as well as low access to high-quality spirometry may play a role in this under-diagnosis of COPD. The information provided in this paper will be helpful for healthcare policy makers in CIS countries to instruct COPD management and prevention strategies and to allocate healthcare resources accordingly.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The prevalence, burden and risk factors associated with chronic obstructive pulmonary disease in Commonwealth of Independent States (Ukraine, Kazakhstan and Azerbaijan): results of the CORE study

Nugmanova

Feshchenko²,

Iashyna³

et al. 2018

BMC Pulm Med

View full text Add to dashboard Cite

show abstract

“…A study using a prevalence model to estimate burden of COPD in 12 Asian countries, reported a COPD prevalence rate of 6.7% in Vietnam [12]. A more recent one conducted on patients in the north of Vietnam indicated the result of 7.1% prevalence [13]. Exacerbations were found to occur in over half of COPD patients [14], resulting in them having to attend hospitals.…”

Section: Introductionmentioning

confidence: 99%

Direct Hospitalization Cost of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Vietnam

Ngo

Bui

et al. 2018

IJERPH

View full text Add to dashboard Cite

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) have been found to contribute, predominantly, to increasing costs of COPD—a major public health issue. This study aimed to fill the gap in literature concerning costs of AECOPD in Vietnam, by examining the direct cost of AECOPD hospitalization and determining potentially associated factors. A cross-sectional study was conducted at the Respiratory Center of Bach Mai Hospital, Hanoi. A total of 57 participants were selected. Information regarding sociodemographic features, clinical characteristics, and hospitalization costs were collected. A multivariate generalized linear regression model was utilized to determine the factors associated with hospitalization costs. The mean total and daily hospitalization cost were 18.3 million VND (SD = 12.9) and 2.5 million VND (SD = 3.2), respectively. Medication cost accounted for 53.9% of hospitalization cost (from 44.0% in the Global Initiative for Chronic Obstructive Lung Disease Classification A (GOLD A) to 55.3% in GOLD C). Patients having GOLD D COPD (Coef. = 5.78; 95% CI = 0.73–10.83), higher age (Coef. = 0.37; 95% CI = 0.13–0.61), and higher duration of hospitalization (Coef. = 1.91; 95% CI = 1.28–2.53) had higher hospitalization costs (p < 0.05). This study suggested that interventions to screen COPD patients as well as provide timely treatment should be conducted widely in the community in order to avoid any unnecessary hospitalization cost, consequently reducing the economic burden of COPD.

show abstract

“…With an estimated 328 million people presenting moderate to severe COPD worldwide, the condition is considered as a major health and economic concern globally, and more specifically in low- and middle-income countries (LMICs) where almost 90% of worldwide COPD deaths are reported [ 2 , 3 ]. Approximately 7.1% of the Vietnamese population (nearly 6.8 million people) have COPD [ 4 ]. These patients occupy roughly 25% of the beds in the respiratory wards of hospitals, at our institution [ 5 ], and nationwide [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…Approximately 7.1% of the Vietnamese population (nearly 6.8 million people) have COPD [ 4 ]. These patients occupy roughly 25% of the beds in the respiratory wards of hospitals, at our institution [ 5 ], and nationwide [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Population Pharmacokinetics and Dose Optimization of Ceftazidime and Imipenem in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease

et al. 2021

View full text Add to dashboard Cite

Background: Ceftazidime and imipenem have been increasingly used to treat Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) due to their extended-spectrum covering Pseudomonas aeruginosa. This study aims to describe the population pharmacokinetic (PK) and pharmacodynamic (PD) target attainment for ceftazidime and imipenem in patients with AECOPD. Methods: We conducted a prospective PK study at Bach Mai Hospital (Viet Nam). A total of 50 (ceftazidime) and 44 (imipenem) patients with AECOPD were enrolled. Population PK analysis was performed using Monolix 2019R1 and Monte Carlo simulations were conducted to determine the optimal dose regimen with respect to the attainment of 60% and 40% fT>MIC for ceftazidime and imipenem, respectively. A dosing algorithm was developed to identify optimal treatment doses. Results: Ceftazidime and imipenem PK was best described by a one-compartment population model with a volume of distribution and clearance of 23.7 L and 8.74 L/h for ceftazidime and 15.1 L and 7.88 L/h for imipenem, respectively. Cockcroft–Gault creatinine clearance represented a significant covariate affecting the clearance of both drugs. Increased doses with prolonged infusion were found to cover pathogens with reduced susceptibility. Conclusions: This study describes a novel and versatile three-level dosing algorithm based on patients’ renal function and characteristic of the infective pathogen to explore ceftazidime and imipenem optimal regimen for AECOPD.

show abstract

Prevalence of COPD by Disease Severity in Men and Women in Northern Vietnam

Cited by 20 publications

References 28 publications

The prevalence, burden and risk factors associated with chronic obstructive pulmonary disease in Commonwealth of Independent States (Ukraine, Kazakhstan and Azerbaijan): results of the CORE study

The prevalence, burden and risk factors associated with chronic obstructive pulmonary disease in Commonwealth of Independent States (Ukraine, Kazakhstan and Azerbaijan): results of the CORE study

Direct Hospitalization Cost of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Vietnam

Population Pharmacokinetics and Dose Optimization of Ceftazidime and Imipenem in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About